Friday 19th September, 2025a
|
08.00
|
Registration
|
|
08:45 - 09:00
|
Welcome
Vickie Lee, Imperial College Healthcare NHS Trust, UK and Mario Salvi, EUGOGO
President
|
|
09:00 - 10:30
|
Pathogenesis
Chair: Colin Dayan and Anja Eckstein
|
|
09:00 - 09:13
|
Thyroid Autoimmunity & TED
Colin Dayan, University of Cardiff, UK
|
|
09:13 - 09:26
|
TED Immunology
Sijie Fang, Shanghai Jiao Tong University, China
|
|
09:26 - 09:39
|
Orbital Fibroblast Biology
Gina-Eva Görtz, University Hospital Essen, Germany
|
|
09:39 - 09:52
|
Animal Models
Anja Eckstein, University Duisburg Essen, Germany
|
|
09:52 – 10:05
|
TED and the Microbiome
Marian Ludgate, Cardiff University School of Medicine, UK
|
|
10:05 - 10:20
|
Panel Discussion
|
|
10:20 - 11:00
|
Coffee Break
|
|
11:00 - 12:30
|
Thyroid Management and Risk Factors
Chair: Karim Meeran and Ilaria Müller
|
|
11:00 - 11:13
|
Thyroid Management in a Changing Landscape
Chrysoula Dosiou, Stanford University School of Medicine, USA
|
|
11:13 - 11:26
|
TED Biomarkers
Hans Olav Ueland, Haukeland University Hospital, Norway
|
|
11:26 - 11:39
|
Definitive Treatment options: Radioiodine vs. Thyroidectomy
Karim Meeran, Imperial College London, UK
|
|
11:39 - 11:52
|
Managing Risk Factors
Milos Zarkovic, University of Belgrade, Serbia
|
|
11:52 - 12:05
|
Total Thyroid Ablation for Graves’ Orbitopathy
Michele Marinò, University of Pisa, Italy
|
|
12:05 – 12:18
|
FcRn Inhibitors
George Kahaly, Mainz University Hospital, Germany
|
|
12:18 - 12:43
|
Panel Discussion
|
|
12:43 - 13:13
|
Industry Symposium
|
|
13:13 - 14:13
|
Lunch
|
|
14:13 - 15:46
|
TED Examination
Chair: Peter Dolman and Bijay Vaidya
|
|
14:13 – 14:26
|
Clinical Assessment
Michael Kazim, Harkness Eye Institute, Columbia University Medical Center, USA
|
|
14:26 - 14:39
|
Imaging
Kunwar Bhatia, Imperial College Healthcare NHS Trust, UK
|
|
14:39 - 14:52
|
Industry Presentation
|
|
14:52 - 15:05
|
Ocular Surface in TED
Andrea Kossler, Stanford University, USA
|
|
15:05- 15:18
|
Ocular Hypertension in TED
Nicole Fichter, ADMEDICO orbital centre, Switzerland
|
|
15:18 - 15:33
|
Thyroid Eye Disease (TED) Phases: Inflammatory Signs vs Disease Progression
Peter Dolman, University of British Columbia, Canada
|
|
15:33 - 15:46
|
Panel Discussion
|
|
15:46 - 16:16
|
Coffee Break
|
|
16:16 - 17:21
|
Diverse Manifestations
Chair: Kelvin Chong and Maria-Cristina Burlacu
|
|
16:16 - 16:29
|
Hypothyroid & Euthyroid TED
Maria-Cristina Burlacu, Cliniques Universitaires Saint-Luc, Belgium
|
|
16:29 - 16:42
|
Ethic Variations in TED Presentations
Gangadhara Sundar, National University Hospital, Singapore
|
|
16:42 - 16:55
|
Pediatric Graves orbitopathy
Peerooz Saeed, Amsterdam University Medical Center, Netherlands
|
|
16:55 – 17:08
|
Phenotypes in Thyroid Eye Disease - predictor to therapeutic response
Jimmy Uddin, Moorfields Eye Hospital, UK
|
|
17:08 - 17:21
|
TED Mimickers
Vickie Lee, Imperial College Healthcare NHS Trust, UK
|
|
17:21 – 17:36
|
Panel Discussion
|
|
17:36
|
Close
|
|
17:30 – 19.00
|
Networking Reception
|
|
Saturday 20th September, 2025
|
08.00
|
Registration
|
|
09:00 -10:33
|
Therapies with Special Targets
Chair: Don Kikkawa and Tomasz Bednarczuk
|
|
09:00 - 09:13
|
IGF-1R Antagonists
Suzanne Freitag, Harvard Medical School, USA
|
|
09:13 - 09:26
|
Teprotumumab: A Review of Efficacy & Longevity
Andrea Kossler, Stanford University, USA
|
|
09:26 - 09:39
|
Tocilizumab in TED
Ilaria Müller, University of Milan, Italy
|
|
09:39 - 09:52
|
Autoantibodies to the TSH receptor – mechanisms of action and new therapeutics
Bernard Rees Smith, FIRS Laboratories, UK
|
|
09:52 - 10:05
|
Adverse Events of the New Targeted Therapies
Marius Stan, Mayo Clinic, USA
|
|
10:05 - 10:18
|
Relapse after Targeted Therapies
Chrysoula Dosiou, Stanford University School of Medicine, USA
|
|
10:18 - 10:33
|
Panel Discussion
|
|
10:33 - 11:03
|
Coffee Break
|
|
11:03 - 12:36
|
Metabolic & Immunomodulatory Therapies
Chair: Chrysoula Dosiou and Onur Konuk
|
|
11:03 – 11:16
|
Statins & Selenium
Michele Marinò, University of Pisa, Italy
|
|
11:16 - 11:29
|
Immunomodulation Options - Should Steroids Still Have a Role?
Mario Salvi, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano., Italy
|
|
11:29 - 11:42
|
When should we use RTX for TED?
Mario Salvi, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milano., Italy and Marius Stan, Mayo Clinic, USA
|
|
11:42 - 11:55
|
Triple therapy as medical decompression for low clinical activity score
(CAS), progressive, Thyroid Eye Disease (TED)
Kelvin Chong, The Chinese University of Hong Kong, Hong Kong
|
|
11:55 - 12:08
|
Local Treatments (Triamcinolone / Botulinum /5 FU)
Onur Konuk, Gazi University Medical School, Turkey
|
|
12:08 - 12:21
|
The Role of Radiotherapy (XRT) for Thyroid Eye Disease (TED)
Peter Dolman, University of British Columbia, Canada
|
|
12:21 - 12:36
|
Panel Discussion
|
|
12:36 - 13:24
|
Lunch
|
|
13:24 - 14:24
|
Panel Discussion: Future Combination Therapies – Q & A
Panel Endocrinologists
Marius Stan, Mayo Clinic, USA
Mario Salvi, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano.,
Italy
Chrysoula Dosiou, Stanford University School of Medicine, USA
Tomasz Bednarczuk, Medical University of Warsaw, Poland
Panel Ophthalmologists
Andrea Kossler, Stanford University, USA
Onur Konuk, Gazi University Medical School, Turkey
Anja Eckstein, University Duisburg Essen, Germany
Don Kikkawa, University of California, San Diego
Panel Otolaryngologist
Jason Brant, University of Wisconsin, USA
|
|
14:24 – 15:04
|
Rapid-Fire Session
Chair: Mario Salvi & Don Kikkawa
|
|
14:24 – 14:27
|
RF01: Artificial Intelligence in Thyroid Eye Disease Patient
Management: Innovations and Applications
Micro Armenti, University of Milan, Italy
|
|
14:27 – 14:30
|
RF02: Molecular Insights into Thyroid Eye Disease via Untargeted
Lipidomics and Metabolomics in a TSHR Mouse Model
Fahimeh Hashemi Arani, University Hospital Essen, Germany
|
|
14:30 – 14:33
|
RF03: Dissecting Orbital Immune Landscapes in Graves''
Orbitopathy: Single-Cell Transcriptomics, Multi-Omics Integration, and MultiMethod Validation
Yuanping Hai, Mainz University, Germany
|
|
14:33 – 14:36
|
RF04: External Validation of a Machine Learning System for Detecting Active Thyroid Eye Disease Using Facial Images in a Spanish Cohort
Antonio Manuel Garrido Hermosilla, Hospital Universitario Virgen Macarena, Spain
|
|
14:36 – 14:39
|
RF05: An effective and cost-effective steroid sparing approach to Thyroid Eye Disease
Robert Nutt, Oxford University Hospital, UK
|
|
14:39 – 14:42
|
RF06: Triglycerides as a Predictor of Activity and Severity in Thyroid Eye
Disease: A Multicenter Study
Hyeong Ju Byeon, Gangnam Severance Hospital, South Korea
|
|
14:42 – 14:45
|
RF07: Depression, anxiety and stress in the Belgian patient suffering from Graves Orbitopathy.
Virgine GS Ninclaus, Ghent University Hospital, Belgium
|
|
14:45 – 14:58
|
RF08: Paediatric Thyroid Eye Disease: Clinical Experience from a quaternary referral centre
Mustafa Al-Asady, Imperial College Healthcare NHS Trust
|
|
14:48 – 14:51
|
RF09: Incidence of Thyroid Eye Disease and Surgical Interventions in
Patients with Graves’ disease treated with Antithyroid medication,
Radioiodine, or Thyroidectomy – A Nationwide Registry-Based Cohort Study
Lena Boulakh, Department of Ophthalmology Rigshospitalet-Glostrup, Denmark
|
|
15:51 – 15:04
|
Travel Grant & Poster Prize Winner Award Ceremony (Mario Salvi)
|
|
15:04 – 15:34
|
Coffee Break
|
|
15:34 – 18:54
|
Surgical Therapies, Debates pre and post Targeted therapy
Chair: Peerooz Saeed and Andrea Kossler
|
|
15:34 - 15:42
|
DON Treatment – Conventional Challenges
Nicola Curro, Fondazione IRCCs Cà Granda Milan, Italy
|
|
15:42 – 15:50
|
Management of Dysthyroid Optic neuropathy: New paradigms
Juliette Abeillon, Hospices Civils de Lyon, France
|
|
15:50 – 15:54
|
Discussion
|
|
15:54 – 16:02
|
Orbital Decompression (Conventional Challenges)
Marta Perez Lopez, Hospital Universitario y Politécnico La Fe, Spain
|
|
16:02 – 16:10
|
Orbital Decompression (Post-Teprotumumab)
Michael Kazim, Harkness Eye Institute, Columbia University Medical Center, USA
|
|
16:10 – 16:14
|
Discussion
|
|
16:14 - 16:22
|
Strabismus Surgery – Aim for Symmetry
Anja Eckstein, University Duisburg Essen, Germany
|
|
16:22 - 16:30
|
Strabismus Surgery Post-Teprotumumab
Madhura Tamhankar, University of Pennsylvania, USA
|
|
16:30 – 16:34
|
Discussion
|
|
16:34 – 16:42
|
Eyelid Surgery in TED
Diego Strianese, University of Naples, Italy
|
|
16:42 – 16:50
|
Surgical Timing Before & After Teprotumumab
Andrea Kossler, Stanford University, USA
|
|
16:50 – 16:54
|
Discussion
|
|
16:54 – 18:00
|
Case Discussion with Experts
Chair: Peerooz Saeed and Vassiliki Bravis
Speakers:
Don Kikkawa, UC San Diego Department of Ophthalmology, USA
Valencia Foo, Singapore National Eye Center, Singapore
Anjana Haridas, Cardiff Eye Unit, University Hospital of Wales, UK
Inga Neumann, University Hospital Essen, Germany
Claire Feeney, Imperial Healthcare NHS Trust, UK
|
|
19:00
|
Gala Dinner – Royal Geographical Society
|
|
a
Sunday 21st September, 2025
|
08.00
|
Registration
|
|
|
Chair: Micheal Kazim & Vickie Lee
|
|
9:00 – 9:10
|
Optimising Outcome Measures in Thyroid Eye Disease (TED):
Bridging the Gap Between Clinical Trials and Real-World Experience
Vickie Lee, Imperial College Healthcare NHS Trust, UK
|
|
9:10 – 9:20
|
New Quality of Life Assessments
Katharina Ponto, Mainz University Hospital, Germany
|
|
9:20 – 9:30
|
Medical Research Survey in TED
Tomasz Bednarczuk, Medical University of Warsaw, Poland
|
|
9:30 – 9:40
|
Establishing a Global Registry for Graves Orbitopathy: Advancing Scientific Knowledge Through Multicenter Academic Collaboration
Micheal Oeverhaus, University Duisburg Essen, Germany
|
|
9:40 - 9:55
|
Panel discussion
|
|
9:55 – 11:10
|
Global Round Table Discussion
Unmet Needs & Ideal Outcome Measures
Round Table Moderators: Milos Zarkovic, Mario Salvi, Nicole Fichter, Claire Feeney, Anja Eckstein, Vickie Lee, Karim Meeran, Tomasz Bednarzuk, Gangadhara Sundar, Don Kikkawa, Michael Kazim and Peter Dolman
|
|
11:10 – 11:50
|
Summary of Round Table Discussions
|
|
11:40 – 11:50
|
Close of Conference
|
|
11:50 – 12:30
|
Coffee Break
|
|
12:30 – 2pm
|
EUGOGO General Assembly for EUGOGO members only
|
|
